All In Biotech

Drug Trial Radar · NCT06467201

SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females

An Open-label, Sequential Dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Human Post-Menopausal Female Volunteers

Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jun 3, 2024

Primary completion

Dec 8, 2024

Study completion Mar 12, 2025

Sponsor

Lead sponsor
Amneal Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Jun 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Female only, from 45 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an Open-label, Sequential dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of KSHN001126 in Healthy Human Post-Menopausal Female Volunteers. The primary objective of the study is to evaluate the safety and tolerability of increasing single doses of KSHN001126 while the secondary objective is to evaluate the plasma PK profile of KSHN001126 and its metabolites (KSHN001167, KSHN001168 and Fulvestrant) following ascending single oral doses of KSHN001126.

Conditions

  • Healthy Postmenopausal Women

Interventions

  • KSHN001126 150mgDrug

    6 subjects will receive single oral dose of 150mg

  • KSHN001126 300mgDrug

    6 subjects will receive single oral dose of 300mg

  • KSHN001126 600mgDrug

    6 subjects will receive single oral dose of 600mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Type, incidence, severity, seriousness, and relatedness of Adverse Events (AEs)Time frame: Upto Day 15 after dosing
  2. Number of participants with abnormal laboratory tests resultsTime frame: Upto Day 15 after dosing
  3. Number of participants with abnormal vital signsTime frame: Upto Day 15 after dosing
  4. Number of participants with abnormal Electrocardiogram readingsTime frame: Upto Day 15 after dosing

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Advanced Pharma CR

    Miami, Florida

  • Health1 Superspeciality Hospital

    Ahmedabad, Gujarat, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.